A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection Genotype 1
- Interventions
- Registration Number
- NCT02219490
- Lead Sponsor
- AbbVie
- Brief Summary
The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic hepatitis C virus genotype 1 (HCV GT1) infection.
- Detailed Description
This study (TOPAZ-I; M14-423), was a Phase 3b, open-label, multicenter study conducted outside of the United States which, together with its companion study TOPAZ-II (M14-222; NCT 02167945) conducted in the United States, was designed with the primary objective of assessing the effect of treatment response on long-term clinical outcomes in adults with chronic HCV GT1 infection with or without compensated cirrhosis, who were either treatment-naïve or interferon/ribavirin (IFN/RBV) treatment- experienced. In both studies, participants were treated with the 3-DAA regimen with or without RBV. This study consisted of a screening period of up to 42 days, a treatment period of either 12 weeks for HCV GT1a-infected subjects without cirrhosis and for HCV GT1b-infected subjects without cirrhosis or with compensated cirrhosis or 24 weeks for GT1a-infected participants with compensated cirrhosis, and a 260-week post-treatment period.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1596
- Males and females at least 18 years old at screening
- Females must be post-menopausal for more than 2 years or surgically sterile or practicing acceptable forms of birth control
- Chronic hepatitis C, genotype 1 infection
- Males must be surgically sterile or agree to practice acceptable forms of birth control
- Screening laboratory result indicating HCV genotype 1 infection
- Use of contraindicated medications within 2 weeks of dosing
- Abnormal laboratory tests
- Current or past clinical evidence of Child-Pugh B or C classification or history of liver decompensation
- Confirmed presence of hepatocellular carcinoma
- History of solid organ transplant
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV) Ribavirin (RBV) Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks. ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV) ABT-333 Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks. ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV) ABT-450/r/ABT-267 Participants with HCV GT1b without cirrhosis received the 3-DAA (ABT-450/ritonavir/ABT-267 and ABT-333) regimen: two 75 mg ABT-450/50 mg ritonavir/12.5 mg ABT-267 tablets taken orally every morning (QD) and one ABT-333 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis and those with HCV GT1b with cirrhosis received the 3-DAA regimen and weight-based ribavirin (RBV; 1000 to 1200 mg divided twice daily per local label) for 12 weeks. Participants with HCV GT1a with cirrhosis received the 3-DAA regimen and weight-based RBV per local label for 24 weeks.
- Primary Outcome Measures
Name Time Method Hepatocellular Carcinoma: Time to Event At Post-Treatment Weeks 52, 104, 156, 208, and 260 Time to hepatocellular carcinoma (HCC) was defined as number of days from 1st day of study drug dosing for subject to date of hepatocellular carcinoma. All HCC was to be included, whether it occurred while subject was still taking study drug or had previously discontinued study drug. If the subject didn't experience the event of interest nor had died (all-cause death), their data was to be censored at the date of their last available assessment. For those with no post-baseline assessment, their data was to be censored on the 1st day of study drug dosing. All-cause death was a censoring event for HCC. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. The pre-specified analysis of hepatocellular carcinoma included pooled data from TOPAZ-I (this study) and the companion study TOPAZ-II (M14-222; NCT02167945).
Liver Decompensation: Time to Event At Post-Treatment Weeks 52, 104, 156, 208, and 260 Time to liver decompensation was defined as number of days from the 1st day of study drug dosing for the participant to the date of liver decompensation. All liver decompensation was to be included, regardless of whether it occurred while the participant was still taking study drug or had previously discontinued study drug. If the participant didn't experience the event of interest nor had died (all-cause death), their data was to be censored at the date of their last available assessment of clinical outcomes. For participants with no post-baseline assessment, their data was to be censored on the 1st day of study drug dosing. All-cause death was a censoring event for liver decompensation. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. The pre-specified analysis of liver decompensation included pooled data from TOPAZ-I (this study) and the companion study TOPAZ-II (M14-222; NCT02167945).
Liver-Related Death: Time to Event At Post-Treatment Weeks 52, 104, 156, 208, and 260 Time to liver-related death was defined as days from the 1st day of study drug dosing for the subject to date of liver-related death. All liver-related deaths were to be included, regardless of whether the death occurred while subject was still taking study drug or had previously discontinued study drug. If the subject didn't experience event of interest nor had died (all-cause death), their data was to be censored at date of last available assessment. For those with no post-baseline assessment, data was to be censored on 1st day of study drug dosing. All-cause death was a censoring event for liver-related death. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. The pre-specified analysis of liver-related death included pooled data from TOPAZ-I (this study) and the companion study TOPAZ-II (M14-222; NCT02167945).
Liver Transplantation: Time to Event At Post-Treatment Weeks 52, 104, 156, 208, and 260 Time to liver transplantation was defined as days from 1st day of study drug dosing for subject to date of liver transplantation. All liver transplantation was to be included, whether it occurred while the subject was still taking study drug or had previously discontinued study drug. If the subject didn't experience event of interest nor had died (all-cause death), their data was to be censored at the date of their last available assessment. For those with no post-baseline assessment, data was to be censored on 1st day of study drug dosing. All-cause death was a censoring event for liver transplantation. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. The pre-specified analysis of liver transplantation included pooled data from TOPAZ-I (this study) and the companion study TOPAZ-II (M14-222; NCT02167945).
All-Cause Death: Time to Event At Post-Treatment Weeks 52, 104, 156, 208, and 260 Time to all-cause death was defined as the number of days from the first day of study drug dosing for the participant to the date of death. All deaths were to be included, regardless of whether the death occurred while the participant was still taking study drug or had previously discontinued study drug. If the participant did not die, their data was to be censored at the date of their last available assessment of clinical outcomes. For participants with no post-baseline assessment, the participant's data was to be censored on the first day of study drug dosing. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. The pre-specified analysis of all-cause death included pooled data from TOPAZ-I (this study) and the companion study TOPAZ-II (M14-222; NCT02167945).
All-Cause Death, Liver-Related Death, Liver Decompensation, Liver Transplantation, Hepatocellular Carcinoma: Time to Event At Post-Treatment Weeks 52, 104, 156, 208, and 260 Time to the composite of clinical outcomes is the time to the first occurrence of all-cause death, liver-related death, liver decompensation, liver transplantation, or hepatocellular carcinoma. All first occurrences were to be included, regardless of whether it occurred while the participant was still taking study drug or had previously discontinued study drug. If the participant did not experience any of these events, their data was to be censored at the date of their last available assessment of clinical outcomes. For participants with no post-baseline assessment, the participant's data was to be censored on the first day of study drug dosing. The event-free survival rates were estimated using Kaplan-Meier methodology and incidence estimates are presented with 95% confidence intervals. Pre-specified analysis included pooled data from this study and from TOPAZ-II; NCT02167945.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) 12 weeks after the last actual dose of study drug SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug. Flanking imputation, where applicable, was used to impute missing data. After applying flanking imputation, if there was no value in the window but there was an HCV RNA value from a local laboratory present, then it was to be imputed into the SVR window. Otherwise, participants with missing data were counted as failures.
Change From Baseline in FibroScan Score by SVR12 Status At the final treatment visit and Post-Treatment Weeks 12, 24, 52, 104, 156, 208, and 260 The FibroScan test is a validated non-invasive test used to assess liver fibrosis in participants with chronic liver disease, and it was performed at study sites where it was available. For participants with Hepatitis C infection, a FibroScan score of 2-7 kPa indicates no liver scarring or mild scarring; a score of 8 or 9 is associated with moderate liver scarring; 9-14 indicates severe liver scarring; and 14 or higher is indicative of advanced liver scarring, cirrhosis. Negative changes from baseline indicate improvement in liver fibrosis.
Trial Locations
- Locations (187)
Akershus Universitetssykehus_MAIN /ID# 132212
🇳🇴Lorenskog, Akershus, Norway
Odense University Hospital /ID# 131029
🇩🇰Odense C, Syddanmark, Denmark
Aarhus Univ Hospital, Skejby /ID# 131030
🇩🇰Aarhus, Denmark
LAIR Centre /ID# 130970
🇨🇦Vancouver, British Columbia, Canada
St James Hospital /ID# 132180
🇮🇪Dublin 8, Dublin, Ireland
Clinique Medicale L'Actuel /ID# 132167
🇨🇦Montreal, Quebec, Canada
Hopital Haut-Lévêque /ID# 131036
🇫🇷Pessac CEDEX, Gironde, France
Hopital Jean Verdier /ID# 135877
🇫🇷Bondy, France
Zentru fur HIV und Heaptogastroenterologie /ID# 131052
🇩🇪Düsseldorf, Nordrhein-Westfalen, Germany
Hospital Donostia /ID# 131144
🇪🇸Donostia, Guipuzcoa, Spain
Izmir Tepecik Training and Research Hospital /ID# 134968
🇹🇷Konak, Izmir, Turkey
Universitaetsklinikum Hamburg-Eppendorf (UKE) /ID# 131051
🇩🇪Hamburg, Germany
Azienda Ospedaliera Universitaria Federico II /ID# 131096
🇮🇹Napoli, Italy
University Hospitals Birmingham NHS Foundation Trust /ID# 131154
🇬🇧Birmingham, United Kingdom
A.O.U. Citta della Salute e della Scienza di Torino /ID# 131100
🇮🇹Turin, Italy
ITESM campus Ciudad de Mexico /ID# 132383
🇲🇽Ciudad de Mexico, Mexico
NHS Lothian /ID# 134368
🇬🇧Edinburgh, United Kingdom
Hospital Universitario A Coruna - CHUAC /ID# 131137
🇪🇸A Coruna, Spain
Hospital Universitario Virgen de la Victoria /ID# 131136
🇪🇸Malaga, Spain
Azienda Ospedaliero-Universitaria di Parma /ID# 132183
🇮🇹Parma, Italy
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie /ID# 131115
🇵🇱Lublin, Lubelskie, Poland
Institutul Nat. de Boli Infectioase /ID# 131124
🇷🇴Bucuresti, Romania
King Abdulaziz Medical City /ID# 145129
🇸🇦Jeddah, Saudi Arabia
Skane University hospital /ID# 131146
🇸🇪Malmo, Skane Lan, Sweden
Karolinska University Hospital Solna /ID# 131145
🇸🇪Solna, Stockholms Lan, Sweden
Sahlgrenska University Hospital /ID# 131147
🇸🇪Gothenburg, Vastra Gotalands Lan, Sweden
Duplicate_NHS Tayside /ID# 132300
🇬🇧Dundee, United Kingdom
Portsmouth Hospitals University NHS Trust /ID# 131158
🇬🇧Portsmouth, United Kingdom
Hospital Universitario de la Princesa /ID# 131131
🇪🇸Madrid, Spain
Barts Health NHS Trust /ID# 132302
🇬🇧London, London, City Of, United Kingdom
The Royal Free London NHS Foundation Trust /ID# 131159
🇬🇧London, London, City Of, United Kingdom
Hospital Universitario Reina Sofia /ID# 131135
🇪🇸Cordoba, Spain
Hospital Universitario 12 de Octubre /ID# 131133
🇪🇸Madrid, Spain
OSI Ezkerraldea-Enkarterri-Cruces /ID# 131143
🇪🇸Barakaldo, Vizcaya, Spain
Hospital Clinico Universitario Lozano Blesa /ID# 132292
🇪🇸Zaragoza, Spain
Hospital General Universitario Santa Lucia /ID# 131139
🇪🇸Cartagena, Murcia, Spain
Duplicate_Nottingham University Nottingham University Hospitals NHS Trust /ID# 131155
🇬🇧Nottingham, Nottinghamshire, United Kingdom
Leeds Teaching Hospitals NHS Trust /ID# 132305
🇬🇧Leeds, United Kingdom
University Hospital Plymouth NHS Trust /ID# 131160
🇬🇧Plymouth, United Kingdom
CHU Bab El Oued /ID# 145420
🇩🇿Algiers, Algeria
CHU Bologhine Hospital /ID# 145421
🇩🇿Algiers, Algeria
CHU Grenoble - Hopital Michallon /ID# 131041
🇫🇷La Tronche, France
A.O.U. Policlinico G. Martino /ID# 132193
🇮🇹Messina, Italy
LMU Klinikum der Universitat Muchen /ID# 131049
🇩🇪Munich, Bayern, Germany
Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie /ID# 131053
🇩🇪Berlin, Germany
Centrum für interdisziplinaere Medizin /ID# 131046
🇩🇪Muenster, Germany
General Hospital of Athens Laiko /ID# 131088
🇬🇷Athens, Attiki, Greece
St Vincent's University Hospital /ID# 132181
🇮🇪Elm Park, Dublin, Ireland
University of Manitoba / Health Scuience Centre / John Buhler Research Centre /ID# 130969
🇨🇦Winnipeg, Manitoba, Canada
Policlinico Agostino Gemelli /ID# 131098
🇮🇹Rome, Lazio, Italy
Nepean Hospital /ID# 130999
🇦🇺Kingswood, New South Wales, Australia
Greenslopes Private Hospital /ID# 131003
🇦🇺Greenslopes, Queensland, Australia
St Vincent's Hospital Melbourne /ID# 131000
🇦🇺Fitzroy Melbourne, Victoria, Australia
The Royal Melbourne Hospital /ID# 130998
🇦🇺Parkville, Victoria, Australia
Medizinische Universitaet Graz /ID# 131018
🇦🇹Graz, Steiermark, Austria
Ordensklinikum Linz GmbH Elisabethinen /ID# 131017
🇦🇹Linz, Oberoesterreich, Austria
Medizinische Universitaet Wien /ID# 131015
🇦🇹Vienna, Wien, Austria
Cliniques Universitaires de Bruxelles Hopital Erasme /ID# 131020
🇧🇪Brussels, Bruxelles-Capitale, Belgium
UCL Saint-Luc /ID# 131019
🇧🇪Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium
Tokuda Hospital Sofia /ID# 131022
🇧🇬Sofia, Bulgaria
Universitair Ziekenhuis Leuven /ID# 131021
🇧🇪Leuven, Vlaams-Brabant, Belgium
UMHAT Sveti Ivan Rilski /ID# 131026
🇧🇬Sofia, Bulgaria
Diagnostic Consultative Center /ID# 131027
🇧🇬Sofia, Bulgaria
Univ Hosp for Active Treat /ID# 131023
🇧🇬Sofia, Bulgaria
UMHAT Sveta Marina /ID# 131025
🇧🇬Varna, Bulgaria
University of Calgary /ID# 134370
🇨🇦Calgary, Alberta, Canada
GI Research & Associates /ID# 132169
🇨🇦Edmonton, Alberta, Canada
Kobenhavns Universitet - Hvidovre Hospital (HH) /ID# 131031
🇩🇰Hvidovre, Hovedstaden, Denmark
Royal Brisbane and Women's Hospital /ID# 131004
🇦🇺Herston, Queensland, Australia
Royal Adelaide Hospital /ID# 131002
🇦🇺Adelaide, South Australia, Australia
Saint John Regional Hospital /ID# 131210
🇨🇦Saint John, New Brunswick, Canada
Toronto General Hospital /ID# 132134
🇨🇦Toronto, Ontario, Canada
Hospital Universitario Central de Asturias /ID# 131138
🇪🇸Oviedo, Asturias, Spain
King's College Hospital NHS Foundation Trusts /ID# 131157
🇬🇧London, United Kingdom
Northern Care Alliance NHS Group /ID# 131156
🇬🇧Salford, United Kingdom
St George's University Hospitals NHS Foundation Trust /ID# 132301
🇬🇧Tooting, United Kingdom
Hospital Universitario Virgen del Rocio /ID# 131134
🇪🇸Sevilla, Spain
Hospital Universitari Son Espases /ID# 131140
🇪🇸Palma de Mallorca, Illes Balears, Spain
Hospital Universitario La Paz /ID# 131132
🇪🇸Madrid, Spain
Westmead Hospital /ID# 130997
🇦🇺Westmead, New South Wales, Australia
Beaumont Hospital /ID# 131089
🇮🇪Beaumont, Dublin, Ireland
Toronto Digestive Disease Asso /ID# 130968
🇨🇦Vaughan, Ontario, Canada
Hospital Universitario Germans Trias i Pujol /ID# 132293
🇪🇸Badalona, Barcelona, Spain
Duplicate_A.O.U. Policlinico S.Orsola-Malpighi /ID# 131095
🇮🇹Bologna, Emilia-Romagna, Italy
General Hospital of Athens Ippokratio /ID# 131057
🇬🇷Athens, Attiki, Greece
CHU Mustapha Bacha /ID# 132130
🇩🇿Algiers, Algeria
CHU de Quebec-Université Laval hôpital CHUL /ID# 132132
🇨🇦Québec, Quebec, Canada
CHU Limoges - Dupuytren 1 /ID# 131038
🇫🇷Limoges CEDEX 1, Franche-Comte, France
Duplicate_Hopital lArchet 2 /ID# 131040
🇫🇷Nice, France
CHRU Pontchaillou /ID# 132173
🇫🇷Rennes, France
CHU Strasbourg - Hopital Civil /ID# 132174
🇫🇷Strasbourg cedex, France
General University Hospital of Alexandroupolis /ID# 131056
🇬🇷Alexandroupolis, Greece
The Lady Davis Carmel Medical Center /ID# 131091
🇮🇱Haifa, Israel
ASST Fatebenefratelli Sacco-Ospedale Sacco /ID# 134372
🇮🇹Milano, Italy
Ospedale S Giuseppe /ID# 132194
🇮🇹Milan, Italy
Azienda Ospedaliera Universitaria Friuli Centrale/Presidio Ospedaliero Universit /ID# 132196
🇮🇹Udine, Italy
Instituto Metropolitano de Inv /ID# 132201
🇲🇽Delegacion Tlalpan, Mexico
Leids Universitair Medisch Centrum /ID# 132204
🇳🇱Leiden, Netherlands
Vancouver Infectious Diseases Centre /ID# 134369
🇨🇦Vancouver, British Columbia, Canada
HCL - Hopital de la Croix-Rousse /ID# 131042
🇫🇷Lyon, France
Hopital Universitaire Purpan Hopital Rangueil /ID# 131035
🇫🇷Toulouse, France
Jewish General Hospital /ID# 132165
🇨🇦Montreal, Quebec, Canada
Royal Victoria Hospital / McGill University Health Centre /ID# 132166
🇨🇦Montreal, Quebec, Canada
Turku University Hospital /ID# 131032
🇫🇮Turku, Finland
Hopital Saint Eloi /ID# 131037
🇫🇷Montpellier CEDEX 5, Herault, France
Toronto Liver Centre /ID# 132168
🇨🇦Toronto, Ontario, Canada
GIRI Gastrointestinal Research Institute /ID# 132171
🇨🇦Vancouver, British Columbia, Canada
Hopital Saint Joseph /ID# 132177
🇫🇷Marseille, Bouches-du-Rhone, France
Universitaetsklinikum Frankfurt /ID# 131055
🇩🇪Frankfurt am Main, Hessen, Germany
Rambam Health Care Campus /ID# 131090
🇮🇱Haifa, Israel
Fondazione di Religione e di Culto Casa Sollievo della Sofferenza /ID# 132190
🇮🇹San Giovanni Rotondo, Foggia, Italy
Ospedale San Raffaele IRCCS /ID# 131093
🇮🇹Milan, Lombardia, Italy
Azienda Ospedaliera Universitaria Ospedali Riuniti /ID# 132195
🇮🇹Foggia, Italy
ASST Santi Paolo e Carlo/Presidio Ospedale San Paolo /ID# 132198
🇮🇹Milan, Italy
Azienda Ospedaliera Universitaria Paolo Giaccone /ID# 132184
🇮🇹Palermo, Italy
Azienda Ospedaliera Universitaria "San Giovanni di Dio e Ruggi d'Aragona /ID# 132192
🇮🇹Salerno, Italy
Centro Hospitalar Universitario Lisboa Central, EPE - Hospital dos Capuchos /ID# 131116
🇵🇹Lisboa, Portugal
Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 131118
🇵🇹Lisboa, Portugal
Institutul Clinic Fundeni /ID# 131121
🇷🇴Sector 2, Bucuresti, Romania
SC Gastromedica SRL /ID# 131127
🇷🇴Iasi, Romania
Krasnoyarsk Regional Center for the Prevention and Control of AIDS /ID# 132278
🇷🇺Krasnoyarsk, Russian Federation
Universitaetsklinikum Freiburg /ID# 131044
🇩🇪Freiburg, Baden-Wuerttemberg, Germany
Gastroenterologische Gemeinschaftspraxis Herne /ID# 131050
🇩🇪Herne, Nordrhein-Westfalen, Germany
Universitaetsklinikum Essen /ID# 131048
🇩🇪Essen, Germany
Medizinische Hochschule Hannover /ID# 131054
🇩🇪Hannover, Germany
The Chaim Sheba Medical Center /ID# 131092
🇮🇱Ramat Gan, Tel-Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 132182
🇮🇱Tel Aviv-Yafo, Tel-Aviv, Israel
Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant Anna /ID# 131102
🇮🇹Cona, Ferrara, Italy
Fondazione PTV Policlinico Tor Vergata /ID# 132185
🇮🇹Rome, Roma, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni /ID# 132188
🇮🇹Bergamo, Italy
Azienda Ospedaliero Universitaria Careggi /ID# 132197
🇮🇹Florence, Italy
Azienda Ospedaliera Niguarda Ca' Granda Hospital /ID# 131104
🇮🇹Milano, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 131097
🇮🇹Milan, Italy
Azienda Ospedaliera Universitaria Federico II /ID# 132191
🇮🇹Napoli, Italy
Universitaetsklinik Heidelberg /ID# 134371
🇩🇪Heidelberg, Baden-Wuerttemberg, Germany
Universitaetsklinikum Tuebingen Medizinische Klinik /ID# 131045
🇩🇪Tubingen, Baden-Wuerttemberg, Germany
South-Ural State Med. Academy /ID# 132274
🇷🇺Chelyabinsk, Russian Federation
Samara State Medical University /ID# 136913
🇷🇺Samara, Russian Federation
Sverdlovsk Regional Clinical Hospital #1 /ID# 132267
🇷🇺Yekaterinburg, Russian Federation
Ministry Nat Guard Hosp Health /ID# 145126
🇸🇦Riyadh, Saudi Arabia
Hospital General de Tijuana /ID# 130972
🇲🇽Tijuana, Baja California, Mexico
Instituto Nacional de Clencias Medicas y Nutricion Salvador Zubrian Departament /ID# 130975
🇲🇽Distrito Federal, Mexico
CIF-BIOTEC/Medica Sur /ID# 134971
🇲🇽Mexico City, Mexico
ID Clinic /ID# 131111
🇵🇱Myslowice, Slaskie, Poland
Duplicate_Institutul National de Boli Infectioase Prof. Dr. Matei Bals /ID# 131120
🇷🇴Sector 2, Bucuresti, Romania
Kuzbass Center for Prevention and Fight agains AIDS /ID# 132269
🇷🇺Kemerovo, Russian Federation
Erasmus Medisch Centrum /ID# 132206
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Academisch Medisch Centrum /ID# 132205
🇳🇱Amsterdam, Netherlands
Stavanger University Hospital /ID# 132211
🇳🇴Stavanger, Norway
Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza /ID# 131106
🇵🇱Bydgoszcz, Kujawsko-pomorskie, Poland
Wojewodzki Specjalistyczny Szpital im. dr. W. Bieganskiego /ID# 131107
🇵🇱Lodz, Lodzkie, Poland
Centro Hospitalar Universitário do Porto, EPE - Hospital Santo António /ID# 131117
🇵🇹Porto, Portugal
Spitalul Clinic de Boli Infectioase Si Pneumoftiziologie Dr. Victor Babes /Id# 131126
🇷🇴Timisoara, Timis, Romania
Medical Company Hepatolog /ID# 132277
🇷🇺Samara, Samarskaya Oblast, Russian Federation
Multidisciplinary Consultative and Diagnostic Center /ID# 131130
🇷🇺Tyumen, Russian Federation
King Khalid University Hospita /ID# 132291
🇸🇦Riyadh, Saudi Arabia
Kantonsspital St. Gallen /ID# 131148
🇨🇭St. Gallen, Sankt Gallen, Switzerland
Inselspital, Universitätsspital Bern /ID# 132294
🇨🇭Bern, Switzerland
Ege University Medical Faculty /ID# 132298
🇹🇷Izmir, Turkey
St. Olavs Hospital HF /ID# 132213
🇳🇴Trondheim, Sor-Trondelag, Norway
Wojewodzki Szpital Zakazny /ID# 131112
🇵🇱Warsaw, Mazowieckie, Poland
Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 131108
🇵🇱Bialystok, Podlaskie, Poland
Centro Hospitalar e Universitario de Coimbra, EPE /ID# 131119
🇵🇹Coimbra, Portugal
Republican Clinical Infectious Diseases Hospital n.a. Professor A. F. Agafonov /ID# 132270
🇷🇺Kazan, Tatarstan, Respublika, Russian Federation
Clinical Infectious Diseases Hospital #1 /ID# 132272
🇷🇺Novosibirsk, Russian Federation
Stavropol State Medical University /ID# 132279
🇷🇺Stavropol, Russian Federation
Tolyatti City Clinical Hospital #1 /ID# 132273
🇷🇺Tolyatti, Russian Federation
NHS Greater Glasgow and Clyde /ID# 131162
🇬🇧Glasgow, Scotland, United Kingdom
Hacettepe University Faculty of Medicine /ID# 131150
🇹🇷Ankara, Turkey
Ankara Univ Medical Faculty /ID# 131151
🇹🇷Ankara, Turkey
Istanbul University Istanbul Medical Faculty /ID# 131153
🇹🇷Istanbul, Turkey
Universitätsspital Zürich /ID# 134881
🇨🇭Zürich, Zuerich, Switzerland
Uludag University Medical Faculty /ID# 132297
🇹🇷Bursa, Turkey
Karadeniz University /ID# 131152
🇹🇷Trabzon, Turkey
Duplicate_University Hospitals Dorset NHS Foundation Trust /ID# 132306
🇬🇧Poole, Dorset, United Kingdom
University Hospital Southampton NHS Foundation Trust /ID# 131161
🇬🇧Southampton, Hampshire, United Kingdom
Ottawa Hospital Research Institute /ID# 132170
🇨🇦Ottawa, Ontario, Canada
Research Institute of Emergency Medicine named after V.I. N.V. Sklifosovsky /ID# 132288
🇷🇺Moscow, Russian Federation
St Vincent's Hospital Sydney /ID# 131001
🇦🇺Darlinghurst, New South Wales, Australia
Central Clinical Hospital of Russian Academy of Science /ID# 132289
🇷🇺Moscow, Russian Federation
Hospital Unversitario Marques de Valdecilla /ID# 131141
🇪🇸Santander, Cantabria, Spain
Helsinki University Hospital /ID# 131034
🇫🇮Helsinki, Uusimaa, Finland
I. M. Sechenov First Moscow State Medical University /ID# 132275
🇷🇺Moscow, Russian Federation
City Clinical Hospital #24 /ID# 132268
🇷🇺Moscow, Russian Federation
CHU de Nantes, Hotel Dieu -HME /ID# 132179
🇫🇷Nantes, Pays-de-la-Loire, France
Cife /Id# 130974
🇲🇽Guadalajara, Jalisco, Mexico
Moscow Clinical Scientific Center n.a. Loginov /ID# 132266
🇷🇺Moscow, Russian Federation